New hope for tough lymphomas: balstilimab trial opens

NCT ID NCT05891821

Recruiting now Disease control Sponsor: Immune Oncology Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 12, 2026 · Last updated Jun 19, 2026 · Updated 1 time

Summary

This study tests a drug called balstilimab in 20 adults with certain lymphomas (classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma) that have returned or not responded to standard treatments. Participants receive the drug every 3 weeks to see if it shrinks tumors and how long any benefit lasts. The goal is to find a new option for people who have run out of standard therapies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hematology Center named after prof. R. Yeolyan
RECRUITING

Yerevan, 0014, Armenia

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma lymphoma primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA